Analytical method validation for HPLC assay of oral anticancer drug exemestane

Fabad Journal of Pharmaceutical Sciences

Volumn 32, Issue 1, 2007, Pages 15-22

  Yavuz, Burçin ^a   Bilensoy, Erem ^a   Şumnu, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bioavailability; Cyclodextrin; Dissolution; Exemestane; HPLC; Inclusion complex; Validation

Indexed keywords

EID: 77953008570     PISSN: 13004182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lynn AG, Ries MS. Top 5 cancers for females and males in the US. J Natl Cancer Inst 87: 867, 1995.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 52: 23-47, 2002.
3. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93: 824-842, 2001. (Pubitemid 32586611)
4. Theobald AJ. Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team. Int J Clin Pract 54:665-669, 2000.
5. Masamura S, Adlercreutz H, Harvey H, et al. Aromatase inhibitor development for the treatment of breast cancer. Breast Cancer Treat 33:19-26, 1995.
6. Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol 59:3, 355-364, 2005. (Pubitemid 40388090)
7. ICI Pakistan Limited. Pharmaceutical and Animal Health - Arimidex (online 25.06.02). Available from: URL: http://www.ici.com.pk/html/products/pharma: arimidex.html
8. Lonning PE. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res. Treat 49:45, 1998.
9. Brodie AMH, Santen RJ. Aromatase and its inhibitors in breast cancer treatment - overview and perspective. Breast Cancer Res. Treat 30: 1, 1994.
10. FDA NDA 20753/S006 - Approved Labeling.
11. Di Salle E, Ornati G, Giudici D, Lassus M, Evans TRJ, Coombes RC. Exemestane (FCE 24304) a new steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol 43:137-143, 1992.
12. Fachinformation: Aromasin (online 27.01.2005). Available from: URL: http: //www.aromasin.ch/deutsch/fachinfo.html
13. Produktinformation: Exemestan (online 27.01.2005). Available from: URL: http: //www.deutscher-apotheker-verlag.de/cgibin /daz/show.cgi?show-intern/na/ 2000/05na-189.html&words- exemestan
14. Yavuz B, Bilensoy E, Şumnu M. Analytical method validation for oral anticancer drug Exemestane. Proceeding of 14th International Pharmaceutical Technology Symposium 191-193, 2008.
15. FDA NDA 20753 - Clinical Pharmacology and Biopharmaceutics Review(s).
16. Breda M, Pianezzola E, Strolin Benedetti M. Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr 620: 225-231, 1993.
17. Allievi C, Zugnoni P, Strolin Benedetti M, Dostert P. Determination of plasma levels of exemestane (FCE 24304), a new irreversible aromatase inhibitor, using liquid chromatography-thermospray mass spectrometry. J. Mass Spectrom 30: 693-697, 1995.
18. Cenacchi V, Baretté S, Cicioni P, Frigerio E, Long J, James J. LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format. J. Pharm. Biomed. Anal 22: 451-460, 2000.
19. Yu C, Mao Y, Miao Y, Jiang J. Determination of Exemestane tablet by RP-HPLC. Yaoxue Jinzhan 30(2): 90-92, 2006.
20. FDA Guideline for Industry, Q2A Text on Validation of Analytical Procedures, March 1995.
21. FDA Guidance for Industry, Q2B Validation of Analytical Procedures: Methodology, November 1996.
22. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS Pharm Set Tech 06(02): E329-E357, 2005.
23. Nakanishi K, Miyazaki S, Masada M, Miyajima K. Effects of Cyclodextrins on biological membrane II. Mechanism of Enhancement on the intestinal absorption of non-absorbable drug by Cyclodextrins. Chem. Pharm. Bull 38: 1684, 1990.
24. Bilensoy E, Doǧan L, Şen M, Hincal A. Complexation behavior of antiestrogen drug tamoxifen citrate with natural and modified b-cyclodextrins. J Incl Phenom Macrocycl Chem 57: 651-655, 2007.